Almirall predicts positive 2021 development of psoriasis product

Dermatology company Almirall retreated in 2020 due to generic competition and Covid-19-related challenges, but the firm expects progress in 2021, aided by two of the firm's newest products.
Photo: Mikkel Aabenhus Hemmingsen / MedWatch
Photo: Mikkel Aabenhus Hemmingsen / MedWatch
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

In early 2020, already, Almirall warned this wouldn't be the best year. Competition from US generic products would have a severe impact, and the firm was facing a series of investments.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading